ETERNAL's 8th and final newsletter is jam packed with information on where you can find our more about the exciting range of results and achievements attained across the whole project as reaches its formal conclusion at the end of August 2026. Latest results, new publications, awrds nominations, final dissemination activity and useful links. It's all here!

ETERNAL's recent final official project dissemination event provided project partners and external guests alike an opportunity to reflect upon and celebrate notable progress made during four years of collaborative research and scale-up for sustainable development of pharmaceutical manufacture, use and disposal, along with notable contributions towards building the the EU’s knowledge base informing environmental risk and ecotoxicity assessemts of pharamceuticals on the one hand and policy development on the other.

This newsletter, the sixth since the ETERNAL project started, provides ample opportunities to dig deeper into both the project’s research illuminating the environmental risks surrounding pharmaceutical manufacture and positive responses from the industry to minimize the risks through technological innovation and standardization for less impactful, more efficient, sustainable and safe by design processes.

A newly published, peer-reviewed paper from a cross-partner team of authors from the ETERNAL project assess the EU's strategy and proposed legislation for pharmaceuticals against the latest scientific knowledge about potential risks to biota and human health, identifying opportunities for strengthening the protection that it offers.

ETERNAL is proud to be a contributing organisation at the 2025 edition of the UK and Ireland’s premier event covering all aspects of the pharmaceutical supply chain, Making Pharmaceuticals, taking place at the Ricoh Arena, Coventry, UK on 29th and 30th April 2025.

The first annual meeting of the group of EU funded projects on Green Pharmaceuticals was held on 10th December 2024 in Brussels. Hosted by the European Commission, representatives of the ETERNAL project and our four sister projects currently within the cluster provided updates on the projects' objectives and progress, and had productive discussions with a range of stakeholders from across the Community.

A short summary of the output from an ETERNAL Industry engagement workshop conducted as part of the Making Pharmaceuticals UK Conference programme held at the Coventry Building Society Arena, Coventry, United Kingdom, on 23rd and 24th April 2024 is now available.

We look forward into the year ahead with a sense of growing excitement as the ETERNAL project’s collaborative research and case study strands gather pace. With several parts of the project’s work programme starting to deliver early results and work progressing strongly across the board, we are looking forward to sharing some of the early highlights and our latest thinking at two notable gatherings of industrialists and researchers from the pharmaceutical and specialty chemicals sectors respectively in the first half of 2024.

A key aspect of evaluating the environmental impact and sustainability of pharmaceuticals is assessing the risk that they may pose to ecosystems. A new public report from the ETERNAL project provides an overview of the current EMA regulation covering the environmental risk assessment of pharmaceuticals, followed by a comparison against the new proposed Regulation and Directive published earlier in 2023. The report concludes with a series of recommendations for integrating the latest scientific knowledge into pharmaceutical risk assessment to help fill gaps in the current and proposed legislation.